Drug Profile
VIS 513
Alternative Names: VIS-513Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Duke-NUS Graduate Medical School Singapore; Massachusetts Institute of Technology
- Developer Serum Institute of India; Visterra
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dengue
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Dengue in USA (Parenteral)
- 27 Sep 2022 Phase-II clinical trials in Dengue in India (Parenteral) (Visterra website, September 2022)
- 01 Nov 2019 Phase I development is ongoing in USA (Visterra pipeline, November 2019)